BioXcel Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BTAI and other ETFs, options, and stocks.About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of artificial intelligence solutions in neuroscience and immuno-oncology. It also focuses on utilizing technology and research to develop therapeutics solutions.
CEOVimal D. Mehta
CEOVimal D. Mehta
Employees37
Employees37
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2017
Founded2017
Employees37
Employees37
BTAI Key Statistics
Market cap57.94M
Market cap57.94M
Price-Earnings ratio-0.41
Price-Earnings ratio-0.41
Dividend yield—
Dividend yield—
Average volume10.10M
Average volume10.10M
High today$7.03
High today$7.03
Low today$3.93
Low today$3.93
Open price$4.92
Open price$4.92
Volume38.44M
Volume38.44M
52 Week high$13.36
52 Week high$13.36
52 Week low$1.17
52 Week low$1.17
BTAI News
TipRanks 9h
BioXcel’s Phase 3 Trial Success for BXCL501Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...
TipRanks 9h
BioXcel Therapeutics announces SERENITY Phase 3 trial met primary endpointBioXcel Therapeutics (BTAI) announced that the SERENITY At-Home Pivotal Phase 3 trial evaluating the safety of BXCL501, the Company’s proprietary, sublingual fi...
Benzinga 13h
BioXcel Stock Surges 19% In After-Hours Trading: What You Need To KnowBioXcel Therapeutics Inc. BTAI experienced significant after-hours momentum, jumping 19.09% to $6.24 in the after-hours trading session on Tuesday, as investors...
People also own
Based on the portfolios of people who own BTAI. This list is generated using Robinhood data, and it’s not a recommendation.